{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:01:42Z","timestamp":1780128102449,"version":"3.54.0"},"reference-count":24,"publisher":"IMR Press","issue":"5","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Youth Professional and Technical Backbone Project of Tianjin Medical University General Hospital","award":["GG-202407"],"award-info":[{"award-number":["GG-202407"]}]},{"name":"Tianjin Municipal Education Commission Research Program Project","award":["2025KJ022"],"award-info":[{"award-number":["2025KJ022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: The mechanism by which kinesin-like protein family 20A (KIF20A) influences prostate cancer progression remains unclear. This study aims to investigate the functional role of KIF20A in prostate cancer and its transcriptional regulatory mechanism via activation of activating transcription factor 2 (ATF2). Methods: Quantitative real-time PCR (qRT-PCR), western blotting, and immunohistochemistry (IHC) were used to assess KIF20A expression in prostate cancer tissues. The chi-square tests was used to analysze the association between KIF20A expression and clinical-pathological features of prostate cancer. A stable KIF20A knockdown prostate cancer cell line was established. The effects of KIF20A expression levels on prostate cancer cell proliferation and invasion were investigated through plate cloning and cell invasion assays. JASPAR was used to predict ATF2 binding sites within the KIF20A promoter region, which were validated by chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Results: KIF20A expression was significantly elevated in prostate cancer tissue compared to their adjacent non-cancerous tissue controls. Furthermore, high KIF20A expression was significantly correlated with tumor grading and staging, as well as lymph node metastasis factors in prostate cancer patients. Knockdown of KIF20A significantly inhibited the proliferation and invasion of prostate cancer cells. ATF2 bound to the promoter region of the KIF20A gene, thereby promoting KIF20A transcription. Conclusions: Under the transcriptional regulation of ATF2, KIF20A expression is significantly upregulated in prostate cancer tissues, thereby promoting the progression of prostate cancer. KIF20A may serve as an independent prognostic factor influencing the prognosis of prostate cancer patients.<\/jats:p>","DOI":"10.31083\/fbl48235","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:25:36Z","timestamp":1780125936000},"source":"Crossref","is-referenced-by-count":0,"title":["Kinesin KIF20A Regulated by ATF2 Transcription Promotes Prostate Cancer Proliferation and Invasion"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5816-1998","authenticated-orcid":true,"given":"Mengchen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Urology, Tianjin Medical University General Hospital, 300070 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1355-6449","authenticated-orcid":true,"given":"Xuhan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Medical University General Hospital, 300070 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Medical University General Hospital, 300070 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nanling County Traditional Chinese Medicine Hospital, 241005 Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-1800","authenticated-orcid":true,"given":"Tianyu","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, 300071 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0158-8487","authenticated-orcid":true,"given":"Baolong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Medical University General Hospital, 300070 Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Weng X, Ma X, Li M, Qin J, Cao S. 259MO Blood-based molecular profiling of Chinese patients with prostate cancer. Annals of Oncology. 2023; 34: S1574.","DOI":"10.1016\/j.annonc.2023.10.385"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Zhou F, Gongqian Z, Guo H, Hu Z, Zhang X, He D, et al. 1795P China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 2023; 34: S971.","DOI":"10.1016\/j.annonc.2023.09.2745"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Farooqi AA, Turgambayeva A, Almabayeva A, Zhanaliyeva M, Orakbay L, Shabanbayeva Z, et al. Mechanistic Insights and Molecular Diagnostics of TMPRSS2-ERG: Overview of the Journey from Regulation of Signaling Landscape in Fusion Positive Prostate Cancer to Appraisal as a Diagnostic Marker. Frontiers in Bioscience (Landmark Edition). 2024; 29: 343.","DOI":"10.31083\/j.fbl2910343"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. The Lancet. Oncology. 2023; 24: 443\u2013456.","DOI":"10.1016\/S1470-2045(23)00148-1"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gao Z, Pang B, Li J, Gao N, Fan T, Li Y. Emerging Role of Exosomes in Liquid Biopsy for Monitoring Prostate Cancer Invasion and Metastasis. Frontiers in Cell and Developmental Biology. 2021; 9: 679527.","DOI":"10.3389\/fcell.2021.679527"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Zhang L, Song W, Shi J, Chen Y. Circ_0084188 Regulates the progression of colorectal cancer through the miR-769-5p\/KIF20A axis. Biochemical Genetics. 2023; 61: 1727\u20131744.","DOI":"10.1007\/s10528-023-10339-3"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Li L, Xue Q, Zhang M, Yang Z, Wang D, Yan G, et al. Upregulation of the key biomarker kinesin family member 20A (KIF20A) is associated with pulmonary artery hypertension. Genomics. 2023; 115: 110705.","DOI":"10.1016\/j.ygeno.2023.110705"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, et al. Down-regulation of RAB6KIFL\/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Research. 2005; 65: 105\u2013112.","DOI":"10.1158\/0008-5472.105.65.1"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wang Q, Wu H, Wu Q, Zhong S. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K\/AKT pathway. Drug Development Research. 2023; 84: 907\u2013921.","DOI":"10.1002\/ddr.22061"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Copello VA, Burnstein KL. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene. 2022; 41: 2824\u20132832.","DOI":"10.1038\/s41388-022-02307-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Laifenfeld D, Karry R, Grauer E, Klein E, Ben-Shachar D. ATF2, a member of the CREB\/ATF family of transcription factors, in chronic stress and consequent to antidepressant treatment: animal models and human post-mortem brains. Neuropsychopharmacology. 2004; 29: 589\u2013597.","DOI":"10.1038\/sj.npp.1300357"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle. 2008; 7: 2341\u20132345.","DOI":"10.4161\/cc.6388"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gozdecka M, Breitwieser W. The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochemical Society Transactions. 2012; 40: 230\u2013234.","DOI":"10.1042\/BST20110630"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Geng L, Chen X, Zhang M, Luo Z. Ubiquitin-specific protease 14 promotes prostate cancer progression through deubiquitinating the transcriptional factor ATF2. Biochemical and Biophysical Research Communications. 2020; 524: 16\u201321.","DOI":"10.1016\/j.bbrc.2019.12.128"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ma J, Chang K, Peng J, Shi Q, Gan H, Gao K, et al. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Journal of Experimental & Clinical Cancer Research. 2018; 37: 145.","DOI":"10.1186\/s13046-018-0809-0"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022; 25: 18\u201327.","DOI":"10.1016\/j.neo.2022.01.001"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research. 2017; 45: W98\u2013W102.","DOI":"10.1093\/nar\/gkx247"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Research. 2024; 52: D174\u2013D182.","DOI":"10.1093\/nar\/gkad1059"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tapper W, Carneiro G, Mikropoulos C, Thomas SA, Evans PM, Boussios S. The Application of Radiomics and AI to Molecular Imaging for Prostate Cancer. Journal of Personalized Medicine. 2024; 14: 287.","DOI":"10.3390\/jpm14030287"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Chen S, Zhao L, Liu J, Han P, Jiang W, Liu Y, et al. Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination. Cancer Letters. 2024; 598: 217105.","DOI":"10.1016\/j.canlet.2024.217105"},{"key":"ref21","unstructured":"Li J, Chen S, Zhao L, Liu J, Han P. Kif20a Inhibitors Enhance the Efficacy of Pd-1 Inhibitors by Enhancing C-Myc Ubiquitination and Breaking Immune Escape in Hepatocellular Carcinoma. Hepatology. 2024; 80: S1746."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, et al. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clinical Cancer Research. 2013; 19: 4508\u20134520.","DOI":"10.1158\/1078-0432.CCR-13-0197"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V. The role of ATF-2 in oncogenesis. BioEssays. 2008; 30: 314\u2013327.","DOI":"10.1002\/bies.20734"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhang X, Bao Q, Li R, Deng X, Cao J, et al. Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer. Journal of Advanced Research. 2025.  (online ahead of print)","DOI":"10.1016\/j.jare.2025.09.028"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/5\/10.31083\/FBL48235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:25:54Z","timestamp":1780125954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/5\/10.31083\/FBL48235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02057-5"],"URL":"https:\/\/doi.org\/10.31083\/fbl48235","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"48235"}}